Olanzapine olanzapine 10 MG Oral Tablet
Indications & Usage Section Olanzapine is an atypical antipsychotic indicated: As oral formulation for the: Treatment of schizophrenia. (1.1) Adults: Efficacy was established in three clinical trials in patients with schizophrenia: two 6-week trials and one maintenance trial. (14.1) Acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. (1.2) Adults: Efficacy was established in three clinical trials in patients with manic or mixed episodes of bipolar I disorder: two 3- to 4-week trials and one maintenance trial. (14.2) Adjunct to valproate or lithium in the treatment of manic or mixed episodes associated with bipolar I disorder. (1.2) Efficacy was established in two 6-week clinical trials in adults (14.2) . Maintenance efficacy has not been systematically evaluated. As Olanzapine Tablets, USP and Fluoxetine in Combination for the: Treatment of depressive episodes associated with bipolar I disorder. (1.5) Efficacy was established with Symbyax (olanzapine and fluoxetine in combination) in adults; refer to the product label for Symbyax. Oral olanzapine tablets, USP are indicated for the treatment of schizophrenia . Efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial [see Clinical Studies (14.1) ] . When deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and hyperlipidemia. Clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see Warnings and Precautions (5.5 , 5.6) ] . Information describing the use of olanzapine tablets in pediatric patients with schizophrenia is approved for Eli Lilly and Company’s olanzapine drug product labeling. However, due to Eli Lilly and Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. Monotherapy — Oral olanzapine tablets, USP are indicated for the Acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. Efficacy was established in three clinical trials in adult patients with manic or mixed episodes of bipolar I disorder: two 3- to 4-week trials and one monotherapy maintenance trial [see Clinical Studies (14.2) ] . When deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and hyperlipidemia. Clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see Warnings and Precautions (5.5 , 5.6) ] . Information describing the use of olanzapine tablets in pediatric patients with bipolar 1 disorder is approved for Eli Lilly and Company’s olanzapine drug product labeling. However, due to Eli Lilly and Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. Adjunctive Therapy to Lithium or Valproate — Oral olanzapine tablets, USP are indicated for the treatment of manic or mixed episodes associated with bipolar I disorder as an adjunct to lithium or valproate. Efficacy was established in two 6-week clinical trials in adults. The effectiveness of adjunctive therapy for longer-term use has not been systematically evaluated in controlled trials [see Clinical Studies (14.2) ] . Information on treating pediatric patients with schizophrenia and bipolar I disorder is approved for Eli Lilly and Company’s olanzapine drug product labeling. However, due to Eli Lilly and Company’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. Oral olanzapine tablets, USP and fluoxetine in combination is indicated for the treatment of depressive episodes associated with bipolar I disorder, based on clinical studies in adult patients. When using olanzapine tablets, USP and fluoxetine in combination, refer to the Clinical Studies section of the package insert for Symbyax. Olanzapine tablets, USP monotherapy is not indicated for the treatment of depressive episodes associated with bipolar I disorder.
REMEDYREPACK INC.
ROUND YELLOW C 48
C 48 ROUND YELLOW
Related Pills
Olanzapine olanzapine 10 MG Oral Tablet
REMEDYREPACK INC.
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
How Supplied Section Olanzapine Tablets USP, 2.5 mg are yellow colored, circular, biconvex uncoated tablets, debossed with ‘C’ on one side and ‘45’ on the other side. Bottles of 30 NDC 65862-561-30 Bottles of 100 NDC 65862-561-01 Bottles of 1000 NDC 65862-561-99 Cartons of 100 (10 x 10) Unit-dose Tablets NDC 65862-561-10 Olanzapine Tablets USP, 5 mg are yellow colored, circular, biconvex uncoated tablets, debossed with ‘C’ on one side and ‘46’ on the other side. Bottles of 30 NDC 65862-562-30 Bottles of 100 NDC 65862-562-01 Bottles of 1000 NDC 65862-562-99 Cartons of 100 (10 x 10) Unit-dose Tablets NDC 65862-562-10 Olanzapine Tablets USP, 7.5 mg are yellow colored, circular, biconvex uncoated tablets, debossed with ‘C’ on one side and ‘47’ on the other side. Bottles of 30 NDC 65862-563-30 Bottles of 100 NDC 65862-563-01 Bottles of 1000 NDC 65862-563-99 Cartons of 100 (10 x 10) Unit-dose Tablets NDC 65862-563-10 Olanzapine Tablets USP, 10 mg are yellow colored, circular, biconvex uncoated tablets, debossed with ‘C’ on one side and ‘48’ on the other side. Bottles of 30 NDC 65862-564-30 Bottles of 100 NDC 65862-564-01 Bottles of 1000 NDC 65862-564-99 Cartons of 100 (10 x 10) Unit-dose Tablets NDC 65862-564-10 Olanzapine Tablets USP, 15 mg are yellow colored, circular, biconvex uncoated tablets, debossed with ‘C’ on one side and ‘49’ on the other side. Bottles of 30 NDC 65862-565-30 Bottles of 100 NDC 65862-565-01 Bottles of 1000 NDC 65862-565-99 Cartons of 100 (10 x 10) Unit-dose Tablets NDC 65862-565-10 Olanzapine Tablets USP, 20 mg are yellow colored, circular, biconvex uncoated tablets, debossed with ‘C’ on one side and ‘50’ on the other side. Bottles of 30 NDC 65862-566-30 Bottles of 100 NDC 65862-566-01 Bottles of 1000 NDC 65862-566-99 Cartons of 100 (10 x 10) Unit-dose Tablets NDC 65862-566-10 Store olanzapine tablets at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. The USP defines controlled room temperature as a temperature maintained thermostatically that encompasses the usual and customary working environment of 20° to 25°C (68° to 77°F); that results in a mean kinetic temperature calculated to be not more than 25°C; and that allows for excursions between 15° and 30°C (59° and 86°F) that are experienced in pharmacies, hospitals, and warehouses. Protect olanzapine tablets from light and moisture.
More pills like ROUND C 48